SG Americas Securities LLC purchased a new stake in shares of Crispr Therapeutics AG (NASDAQ:CRSP) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 18,504 shares of the company’s stock, valued at approximately $758,000.
Several other hedge funds have also recently modified their holdings of CRSP. NEXT Financial Group Inc increased its position in shares of Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares during the period. Benjamin Edwards Inc. increased its position in shares of Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after purchasing an additional 268 shares during the period. Coastal Investment Advisors Inc. acquired a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $26,000. US Bancorp DE increased its position in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after purchasing an additional 526 shares during the period. Finally, BSW Wealth Partners acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at $39,000. Institutional investors own 49.82% of the company’s stock.
CRSP has been the topic of several research analyst reports. BidaskClub cut Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Roth Capital lifted their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Canaccord Genuity lifted their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a report on Wednesday, November 20th. Finally, ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $69.54.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by insiders.
Shares of NASDAQ CRSP traded down $0.67 during mid-day trading on Friday, reaching $65.36. The company had a trading volume of 737,055 shares, compared to its average volume of 1,650,207. The company has a 50-day moving average price of $58.93 and a two-hundred day moving average price of $48.44. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics AG has a 1-year low of $22.22 and a 1-year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, sell-side analysts forecast that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: What is intrinsic value?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.